Expanded distribution agreement with Novo Nordisk

Celliance, a subsidiary of Serologicals, announced the execution of an expanded four-year supply agreement with Novo Nordisk that provides Celliance the worldwide exclusive right to distribute Novo Nordisk's recombinant human insulin in the cell culture market.

David Dodd, president and chief executive officer of Serologicals, commented on the supply agreement, stating: "We are very pleased to have concluded this milestone agreement with Novo Nordisk.

"It represents years of hard work and successful collaboration on the part of both companies.

"Our relationship with Novo Nordisk began more than a decade ago when one of our predecessor companies began distributing Novo Nordisk's insulin into the cell culture market.

"Our colleagues at Novo Nordisk were quick to realise the importance of this market.

"They permitted us to develop it by affording us a dependable supply of the highest quality recombinant human insulin for our customers.

"The agreement that we just concluded allows us to renew our commitment to our cell culture customers for another four years.

"We will continue to market this important product to our customers under our Incelligent brand".

Jesper Hoiland, Novo Nordisk's senior vice president of international operations, said: "Novo Nordisk and Celliance have worked closely to build a leading position in the insulin segment of the global market for cell culture media.

"The new agreement creates a strong platform for increased growth and keeps leadership also in this segment".

Celliance offers an expanding array of bioprocessing products and services including diagnostic products and cell culture media supplements.

Key products include Ex-cyte, the largest selling cell growth supplement, Probumin, a proprietary line of bovine serum albumin and Incelligent, recombinant human insulin.

It is also the world's leading provider of monoclonal antibodies for the blood typing industry.